Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Lett. 2012 Feb 14;322(1):58–69. doi: 10.1016/j.canlet.2012.02.005

Figure 7.

Figure 7

K-Ras mutations contribute to the everolimus-induced ERK signal. (A) The K-Ras mt PANC-1 cells were subjected to western blotting after treated first with everolimus and then exposed to 10% FBS, EGF, FGF2, HGF and IGF-1, as indicated on the top of the panel. (B) The experiment was repeated with using NVP-AEW541. (C) The empty vector and K-Ras shRNA expressing PANC-1 cells were examined by western blotting after treated first with everolimus first and then with IGF-1. (D) The empty vector and K-Ras shRNA expressing PANC-1 cells, treated as described above in B, were examined by by BrdU labeling assay. The experiment was repeated three times and the data was presented as mean ± SD. **, p < 0.01.